Following people with long COVID for 4 years to find what shapes recovery
Follows 400 adults with long COVID to study symptoms, fatigue and blood vessel health.
Plain-language title generated from the registry record
Registry title: Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)
Key facts
- Where
- Salamanca, SpainSee the site
Where in Spain
- Av. de Portugal 83. Planta 2Salamanca, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto de Investigación Biomédica de Salamanca
- Trial code
- NCT07295483
- Record updated
- 12 March 2026
- Original description
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.Read full original descriptionShow less
To Analyze the Determining Factors in the Evolution of Subjects Diagnosed With Long COVID at Four Years of Follow-up. BioICOPER Follow-up Study.
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.
The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort.
Advanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.
Inclusion: Adults ≥18 years old; Confirmed previous SARS-CoV-2 infection; Diagnosis of long COVID according to WHO criteria; Participation in the baseline BioICOPER study; Signed informed consent for re-evaluation.
Exclusion: Acute illness preventing participation; Cognitive or physical impairment limiting data collection; Age < 18 years old; Withdrawal of informed consent.